Additionally, MTX has demonstrated efficacy when paired with anti-tumor necrosis factor-alpha (TNF-α) drugs in the treatment of individuals suffering from ulcerative colitis, breast cancer, lung carcinoma, head and neck malignancies, and ovarian carcinoma (Chande et al. 2014). Here, TNF is linked to ulcerative colitis.